Advertisement

Cancer Immunology, Immunotherapy

, Volume 59, Issue 1, pp 35–46 | Cite as

The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells

  • Evelien L. J. M. Smits
  • Nathalie Cools
  • Eva Lion
  • Kirsten Van Camp
  • Peter Ponsaerts
  • Zwi N. Berneman
  • Viggo F. I. Van TendelooEmail author
Original Article

Abstract

Immunotherapy for leukemia is a promising targeted strategy to eradicate residual leukemic cells after standard therapy, in order to prevent relapse and to prolong the survival of leukemia patients. However, effective anti-leukemia immune responses are hampered by the weak immunogenicity of leukemic cells. Therefore, much effort is made to identify agents that could increase the immunogenicity of leukemic cells and activate the immune system. Synthetic agonists of Toll-like receptor (TLR)7 and TLR8 are already in use as anticancer treatment, because of their ability to activate several immune pathways simultaneously, resulting in effective antitumor immunity. However, for leukemic cells little is known about the expression of TLR7/8 and the direct effects of their agonists. We hypothesized that TLR7/8 agonist treatment of human acute myeloid leukemia (AML) cells would lead to an increased immunogenicity of AML cells. We observed expression of TLR7 and TLR8 in primary human AML cells and AML cell lines. Passive pulsing of primary AML cells with the TLR7/8 agonist R-848 resulted in increased expression of MHC molecules, production of proinflammatory cytokines, and enhanced allogeneic naïve T cell-stimulatory capacity. These effects were absent or suboptimal if R-848 was administered intracellularly by electroporation. Furthermore, when AML cells were cocultured with allogeneic PBMC in the presence of R-848, interferon (IFN)-γ was produced by allogeneic NK and NKT cells and AML cells were killed. In conclusion, the immunostimulatory effect of the TLR7/8 agonist R-848 on human AML cells could prove useful for the design of TLR-based immunotherapy for leukemia.

Keywords

TLR7 TLR8 R-848 AML Immunotherapy 

Notes

Acknowledgments

This work was supported by Grant no. G.0370.08 and no. G.0082.08 of the Fund for Scientific Research, Flanders, Belgium (FWO-Vlaanderen), by research grants of the Foundation Against Cancer (Stichting tegen Kanker), by Grant no. 802 of the Antwerp University Concerted Research Action (BOF-GOA), by a Methusalem grant of the Antwerp University and by a part of the Interuniversity Attraction Poles (IAP) programme #P6/41 financed by the Belgian Government. Part of this research was kindly supported by the Antwerp University Hospital (UZA). E. L. J. M. Smits holds a fellowship of the Stichting Emmanuel van der Schueren of the Vlaamse Liga tegen Kanker (VLK). E. Lion was funded by a PhD grant of the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen).

References

  1. 1.
    Hornung V, Rothenfusser S, Britsch S et al (2002) Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531–4537PubMedGoogle Scholar
  2. 2.
    Zarember KA, Godowski PJ (2002) Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 168:554–561PubMedGoogle Scholar
  3. 3.
    Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801CrossRefPubMedGoogle Scholar
  4. 4.
    Jurk M, Heil F, Vollmer J et al (2002) Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 3:499CrossRefPubMedGoogle Scholar
  5. 5.
    Schon MP, Schon M (2008) TLR7 and TLR8 as targets in cancer therapy. Oncogene 27:190–199CrossRefPubMedGoogle Scholar
  6. 6.
    Wagner TL, Ahonen CL, Couture AM et al (1999) Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 191:10–19CrossRefPubMedGoogle Scholar
  7. 7.
    Gibson SJ, Lindh JM, Riter TR et al (2002) Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 218:74–86CrossRefPubMedGoogle Scholar
  8. 8.
    Stary G, Bangert C, Tauber M et al (2007) Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 204:1441–1451CrossRefPubMedGoogle Scholar
  9. 9.
    Wagner TL, Horton VL, Carlson GL et al (1997) Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine 9:837–845CrossRefPubMedGoogle Scholar
  10. 10.
    Vasilakos JP, Smith RM, Gibson SJ et al (2000) Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol 204:64–74CrossRefPubMedGoogle Scholar
  11. 11.
    Tomai MA, Imbertson LM, Stanczak TL et al (2000) The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 203:55–65CrossRefPubMedGoogle Scholar
  12. 12.
    Otero M, Calarota SA, Felber B et al (2004) Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine 22:1782–1790CrossRefPubMedGoogle Scholar
  13. 13.
    Thomsen LL, Topley P, Daly MG et al (2004) Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22:1799–1809CrossRefPubMedGoogle Scholar
  14. 14.
    Smits EL, Ponsaerts P, Berneman ZN et al (2008) The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 13:859–875CrossRefPubMedGoogle Scholar
  15. 15.
    Sauder DN, Smith MH, Senta-McMillian T et al (2003) Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother 47:3846–3852CrossRefPubMedGoogle Scholar
  16. 16.
    Sioud M, Floisand Y (2007) TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response. Eur J Immunol 37:2834–2846CrossRefPubMedGoogle Scholar
  17. 17.
    Bohnhorst J, Rasmussen T, Moen SH et al (2006) Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 20:1138–1144CrossRefPubMedGoogle Scholar
  18. 18.
    Spaner DE, Masellis A (2007) Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia 21:53–60CrossRefPubMedGoogle Scholar
  19. 19.
    Jego G, Bataille R, Geffroy-Luseau A et al (2006) Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 20:1130–1137CrossRefPubMedGoogle Scholar
  20. 20.
    Pellacani A, Tosi P, Zinzani PL et al (1999) Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells. Leuk Lymphoma 33:147–153PubMedGoogle Scholar
  21. 21.
    Spaner DE, Shi Y, White D et al (2006) Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 20:286–295CrossRefPubMedGoogle Scholar
  22. 22.
    Smits EL, Ponsaerts P, Van de Velde AL et al (2007) Proinflammatory response of human leukemic cells to dsRNA transfection linked to activation of dendritic cells. Leukemia 21:1691–1699CrossRefPubMedGoogle Scholar
  23. 23.
    Ponsaerts P, Van Tendeloo VF, Cools N et al (2002) mRNA-electroporated mature dendritic cells retain transgene expression, phenotypical properties and stimulatory capacity after cryopreservation. Leukemia 16:1324–1330CrossRefPubMedGoogle Scholar
  24. 24.
    Fischer K, Andreesen R, Mackensen A (2002) An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity. J Immunol Methods 259:159–169CrossRefPubMedGoogle Scholar
  25. 25.
    Caron G, Duluc D, Fremaux I et al (2005) Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol 175:1551–1557PubMedGoogle Scholar
  26. 26.
    Nishimura M, Naito S (2005) Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 28:886–892CrossRefPubMedGoogle Scholar
  27. 27.
    Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995CrossRefPubMedGoogle Scholar
  28. 28.
    Mazzoni A, Segal DM (2004) Controlling the Toll road to dendritic cell polarization. J Leukoc Biol 75:721–730CrossRefPubMedGoogle Scholar
  29. 29.
    Corthals SL, Wynne K, She K et al (2006) Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. Br J Haematol 132:452–458PubMedGoogle Scholar
  30. 30.
    Maratheftis CI, Giannouli S, Spachidou MP et al (2007) RNA interference of interferon regulatory factor-1 gene expression in THP-1 cell line leads to Toll-like receptor-4 overexpression/activation as well as up-modulation of annexin-II. Neoplasia 9:1012–1020CrossRefPubMedGoogle Scholar
  31. 31.
    Maratheftis CI, Andreakos E, Moutsopoulos HM et al (2007) Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin Cancer Res 13:1154–1160CrossRefPubMedGoogle Scholar
  32. 32.
    Burns RP Jr, Ferbel B, Tomai M et al (2000) The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans’ cells. Clin Immunol 94:13–23CrossRefPubMedGoogle Scholar
  33. 33.
    Bernstein DI, Harrison CJ, Tomai MA et al (2001) Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J Infect Dis 183:844–849CrossRefPubMedGoogle Scholar
  34. 34.
    Schon M, Bong AB, Drewniok C et al (2003) Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95:1138–1149PubMedCrossRefGoogle Scholar
  35. 35.
    Sun R, Tian Z, Kulkarni S et al (2004) IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners. J Immunol 172:5648–5655PubMedGoogle Scholar
  36. 36.
    Vredevoe DL, Widawski M, Fonarow GC et al (2004) Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure. Am J Cardiol 93:1007–1011CrossRefPubMedGoogle Scholar
  37. 37.
    Huang B, Zhao J, Li H et al (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65:5009–5014CrossRefPubMedGoogle Scholar
  38. 38.
    Averett DR, Fletcher SP, Li W et al (2007) The pharmacology of endosomal TLR agonists in viral disease. Biochem Soc Trans 35:1468–1472CrossRefPubMedGoogle Scholar
  39. 39.
    Diebold SS, Kaisho T, Hemmi H et al (2004) Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529–1531CrossRefPubMedGoogle Scholar
  40. 40.
    Kariko K, Buckstein M, Ni H et al (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23:165–175CrossRefPubMedGoogle Scholar
  41. 41.
    Linn YC, Hui KM (2003) Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma 44:1457–1462CrossRefPubMedGoogle Scholar
  42. 42.
    Passweg JR, Tichelli A, Meyer-Monard S et al (2004) Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 18:1835–1838CrossRefPubMedGoogle Scholar
  43. 43.
    Tanaka J, Asaka M, Imamura M (2005) Potential role of natural killer cell receptor-expressing cells in immunotherapy for leukemia. Int J Hematol 81:6–12CrossRefPubMedGoogle Scholar
  44. 44.
    Ruggeri L, Mancusi A, Perruccio K (2005) Natural killer cell alloreactivity for leukemia therapy. J Immunother 28:175–182CrossRefPubMedGoogle Scholar
  45. 45.
    Seino K, Motohashi S, Fujisawa T et al (2006) Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci 97:807–812CrossRefPubMedGoogle Scholar
  46. 46.
    Kalinski P, Giermasz A, Nakamura Y et al (2005) Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 42:535–539CrossRefPubMedGoogle Scholar
  47. 47.
    Ruggeri L, Mancusi A, Burchielli E et al (2006) Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation. Cytotherapy 8:554–558CrossRefPubMedGoogle Scholar
  48. 48.
    Moretta L, Locatelli F, Moretta A (2008) Alloreactive natural killer cells in targeting high-risk leukaemias. Ann Rheum Dis 67(Suppl 3):iii39–iii43CrossRefPubMedGoogle Scholar
  49. 49.
    Costello RT, Fauriat C, Rey J et al (2004) Immunobiology of haematological malignant disorders: the basis for novel immunotherapy protocols. Lancet Oncol 5:47–55CrossRefPubMedGoogle Scholar
  50. 50.
    Hart OM, Athie-Morales V, O’Connor GM et al (2005) TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 175:1636–1642PubMedGoogle Scholar
  51. 51.
    Gorski KS, Waller EL, Bjornton-Severson J et al (2006) Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol 18:1115–1126CrossRefPubMedGoogle Scholar
  52. 52.
    Sawaki J, Tsutsui H, Hayashi N et al (2007) Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways. Int Immunol 19:311–320CrossRefPubMedGoogle Scholar
  53. 53.
    Alter G, Suscovich TJ, Teigen N et al (2007) Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J Immunol 178:7658–7666PubMedGoogle Scholar
  54. 54.
    Girart MV, Fuertes MB, Domaica CI et al (2007) Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J Immunol 179:3472–3479PubMedGoogle Scholar
  55. 55.
    Degli-Esposti MA, Smyth MJ (2005) Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol 5:112–124CrossRefPubMedGoogle Scholar
  56. 56.
    Biassoni R (2008) Natural killer cell receptors. Adv Exp Med Biol 640:35–52CrossRefPubMedGoogle Scholar
  57. 57.
    Verheyden S, Demanet C (2008) NK cell receptors and their ligands in leukemia. Leukemia 22:249–257CrossRefPubMedGoogle Scholar
  58. 58.
    Ogasawara K, Lanier LL (2005) NKG2D in NK and T cell-mediated immunity. J Clin Immunol 25:534–540CrossRefPubMedGoogle Scholar
  59. 59.
    Moretta A, Bottino C, Vitale M et al (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197–223CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Evelien L. J. M. Smits
    • 1
  • Nathalie Cools
    • 1
  • Eva Lion
    • 1
  • Kirsten Van Camp
    • 1
  • Peter Ponsaerts
    • 1
  • Zwi N. Berneman
    • 1
    • 2
  • Viggo F. I. Van Tendeloo
    • 1
    • 2
    Email author
  1. 1.Vaccine and Infectious Disease Institute (VIDI), Laboratory of Experimental Hematology, Faculty of MedicineUniversity of AntwerpAntwerpBelgium
  2. 2.Center for Cellular Therapy and Regenerative MedicineAntwerp University HospitalAntwerpBelgium

Personalised recommendations